Objective: BYSH, a herbal formula, was evaluated for efficacy and safety in a pilot study for patients with advanced
hormone refractory prostate cancer (HRPC). Patients and Methods: The pilot study was designed as a singlecenter
open-label trial. Patients with HRPC were treated with BYSH for 24 weeks. The primary end point was the changes
in serum prostate-specific antigen (PSA) level. Safety parameters such as liver and renal functions were monitored during
the study period. Results: Ten patients were eligible for the study. Most of them had stable PSA levels while taking
BYSH. However, at the end of the BYSH treatment, the level of PSA increased. The median survival from diagnosis of
HRPC was 16.4 months. Liver and renal functions remained normal. BYSH was well tolerated and no patient reported
adverse events during the study period. Conclusion: Although it is inappropriate to make a conclusion based on the pilot
study results, the trend of improvement is obvious. Further investigations should be conducted to demonstrate its clinical
benefits. We have also briefly reviewed some plant products which are patented and also available in market.
Keywords: Complementary medicine, herbal formula, HRPC, prostate cancer, PSA, Saw palmetto.
Rights & PermissionsPrintExport